Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 1;8(3):633-639.
doi: 10.1039/c6md00644b. eCollection 2017 Mar 1.

Synthesis and antitumor mechanism of a new iron(iii) complex with 5,7-dichloro-2-methyl-8-quinolinol as ligands

Affiliations

Synthesis and antitumor mechanism of a new iron(iii) complex with 5,7-dichloro-2-methyl-8-quinolinol as ligands

Bi-Qun Zou et al. Medchemcomm. .

Abstract

A new iron(iii) complex with 5,7-dichloro-2-methyl-8-quinolinol (HClMQ) as ligands, i.e., [Fe(ClMQ)2Cl] (1), was synthesized and evaluated for its anticancer activity. Compared to the HClMQ ligand, complex 1 showed a higher cytotoxicity towards a series of tumor cell lines, including Hep-G2, BEL-7404, NCI-H460, A549, and T-24, with IC50 values in the range of 5.04-14.35 μM. Notably, the Hep-G2 cell line was the most sensitive to complex 1. Mechanistic studies indicated that complex 1 is a telomerase inhibitor targeting c-myc G-quadruplex DNA and can trigger cell apoptosis via inducing cell cycle arrest and DNA damage.

PubMed Disclaimer

Figures

Scheme 1
Scheme 1. Synthetic route of complex 1.
Fig. 1
Fig. 1. Crystal structure of complex 1 with atom labeling.
Fig. 2
Fig. 2. Cellular uptake and distribution of complex 1 (5 μM) and cisplatin (10 μM) by Hep-G2 cells in 24 h at 37 °C. The metal contents in the whole cell (A) and in different cellular fractions (B) were measured using ICP-MS. The control cells were treated with a vehicle (TBS buffer with 1% DMSO). The data are presented as “mean ± SD” from three independent measurements.
Fig. 3
Fig. 3. qRT-PCR analysis of the expression levels of hTERT and c-myc in the Hep-G2 cells treated with complex 1. The Hep-G2 cells (5 × 105) were treated with complex 1 (5 μM) for 24 h. The total RNA in the cells was extracted and subjected to reverse transcription, followed by PCR for hTERT, c-myc and GAPDH (control).
Fig. 4
Fig. 4. Western blot analysis of the expression of hTERT and c-myc bcl-2 in the Hep-G2 cells treated with complex 1 (5 μM) for 24 h. (A) Gel image. (B) Densitometric analysis of the protein bands of hTERT and c-myc (normalized with the β-actin band). The relative expression level of each band is calculated as follows: the density of each band/the density of the β-actin band. Mean ± SD was calculated from three independent measurements.
Fig. 5
Fig. 5. Transfection of the EGFP (A) and c-myc (B) plasmid vectors in the Hep-G2 cells. The EGFP-carrying plasmid vector (2 μg) and the c-myc-carrying plasmid vector (2 μg) were transfected into the Hep-G2 cells using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA). Complex 1 (5 μM) was then added into the medium 6 h after the transfection. After a 24 h incubation, the cells were imaged using a Nikon TE2000 (Japan) scanning fluorescence microscope (A) and examined using a multimode plate reader and a luciferase reporter gene assay kit (B).
Fig. 6
Fig. 6. Cell cycle arrest induced by complex 1 (5 μM) in the Hep-G2 cells.
Fig. 7
Fig. 7. Complex 1-induced DNA damage in the Hep-G2 cells. The cells were treated with complex 1 (5 μM, B) and 1% DMSO solution (control, A) for 24 h and then analyzed by the comet assay. The length of the tail reflects the degree of DNA damage in cells.
Fig. 8
Fig. 8. Apoptosis effect on the Hep-G2 cells treated with complex 1 (5 μM) for 24 h.

Similar articles

Cited by

References

    1. Maji B., Bhattacharya S. Chem. Commun. 2014;50:6422–6438. - PubMed
    1. Franceschin M., Rizzo A., Casagrande V., Salvati E., Alvino A., Altieri A., Ciammaichella A., Lachettini S., Leonetti C., Ortaggi G., Porru M., Bianco A., Biroccio A. ChemMedChem. 2012;7:2144–2154. - PubMed
    1. Karim N. H. A., Mendoza O., Shivalingam A., Thompson A. J., Ghosh S., Kuimova M. K., Vilar R. RSC Adv. 2014;4:3355–3363.
    1. Pickard A., Liu F., Bartenstein T. F., Haines L. G., Levine K. E., Kucera G. L., Bierbach U. Chem. – Eur. J. 2014;20:16174–16187. - PMC - PubMed
    1. Muller S., Rodriguez R. Expert. Rev. Clin. Pharmacol. 2014;7:663–679. - PubMed

LinkOut - more resources